A Perspective Study on the RTK, PI3K, B‐Raf, CDK and the Multi‐Protein Targeting in Medicinal Chemistry
出版年份 2022 全文链接
标题
A Perspective Study on the RTK, PI3K, B‐Raf, CDK and the Multi‐Protein Targeting in Medicinal Chemistry
作者
关键词
-
出版物
CHEMISTRY & BIODIVERSITY
Volume 19, Issue 10, Pages -
出版商
Wiley
发表日期
2022-09-07
DOI
10.1002/cbdv.202200328
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action
- (2021) Rong Chen et al. Blood Cancer Journal
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
- (2021) Jing Wu et al. CLINICAL CANCER RESEARCH
- Umbralisib: First Approval
- (2021) Sohita Dhillon et al. DRUGS
- Trilaciclib: First Approval
- (2021) Sohita Dhillon DRUGS
- Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma
- (2021) Kami Maddocks Clinical Lymphoma Myeloma & Leukemia
- Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
- (2021) Kerrington Powell et al. Translational Oncology
- Design, synthesis and in silico insights of new 7,8-disubstituted-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione derivatives with potent anticancer and multi-kinase inhibitory activities
- (2020) Abdalla R. Mohamed et al. BIOORGANIC CHEMISTRY
- A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
- (2019) Pauline T. Lukey et al. EUROPEAN RESPIRATORY JOURNAL
- Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
- (2019) Weiyan Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors
- (2019) Ahmed M. El Kerdawy et al. JOURNAL OF MOLECULAR MODELING
- Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S
- (2019) Qiannan Li et al. ACS Medicinal Chemistry Letters
- Single and dual targeting of mutant EGFR with an allosteric inhibitor
- (2019) Ciric To et al. Cancer Discovery
- Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
- (2019) Viktoriya Ivasiv et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- Conceptual Evolution of Cell Signaling
- (2019) Arathi Nair et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
- (2019) Ali S. Alzahrani SEMINARS IN CANCER BIOLOGY
- A Phase 1 and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients With Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors
- (2019) Mark W. Kieran et al. CLINICAL CANCER RESEARCH
- Structure-guided development of purine amide, hydroxamate, and amidoxime for the inhibition of non-small cell lung cancer
- (2019) Meng-Ruo Huang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A Phase 1 Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
- (2019) Ryan J. Sullivan et al. MOLECULAR CANCER THERAPEUTICS
- INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)
- (2019) Eddy W. Yue et al. ACS Medicinal Chemistry Letters
- Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Steven T. Bird et al. JAMA Oncology
- Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
- (2018) Carlo Vancheri et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045
- (2018) Peng Zhao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Dual or multi-targeting inhibitors: The next generation anticancer agents
- (2018) Nulgumnalli Manjunathaiah Raghavendra et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer
- (2018) Johann S. Bergholz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
- (2018) Jose Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
- (2018) Yongtao Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
- (2018) Byoung Chul Cho et al. LUNG CANCER
- Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2018) Gerald Edelman et al. ONCOLOGIST
- Structural insights into drug development strategy targeting EGFR T790M/C797S
- (2018) Su-Jie Zhu et al. Oncotarget
- Activity of roniciclib in medullary thyroid cancer
- (2018) Shu-Fu Lin et al. Oncotarget
- Buparlisib is a brain penetrable pan-PI3K inhibitor
- (2018) Mark C. de Gooijer et al. Scientific Reports
- Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
- (2018) Alison Palumbo et al. ANNALS OF PHARMACOTHERAPY
- Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
- (2018) Jing-hua Pan et al. Cancer Management and Research
- Duvelisib: First Global Approval
- (2018) Hannah A. Blair DRUGS
- Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
- (2018) Marcus D. Goncalves et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance
- (2018) Lu Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance
- (2017) Yanmin Zhang et al. Journal of Chemical Information and Modeling
- Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF V600E mutant cancer
- (2017) Sung Pyo Hong et al. LIFE SCIENCES
- Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo
- (2017) Edward J. Hartsough et al. MOLECULAR CANCER THERAPEUTICS
- Inhibitors of cyclin-dependent kinases as cancer therapeutics
- (2017) Steven R. Whittaker et al. PHARMACOLOGY & THERAPEUTICS
- Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
- (2016) P. M. Barr et al. BLOOD
- Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
- (2016) William J. Scott et al. ChemMedChem
- Multitarget Drug Discovery and Polypharmacology
- (2016) Maria Laura Bolognesi et al. ChemMedChem
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Descriptors and their selection methods in QSAR analysis: paradigm for drug design
- (2016) Danishuddin et al. DRUG DISCOVERY TODAY
- Osimertinib: First Global Approval
- (2016) Sarah L. Greig DRUGS
- PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
- (2016) Vivek Asati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)
- (2016) Carmen Di Giovanni et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC
- (2016) Melissa Bersanelli et al. Journal of Thoracic Oncology
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K and PI3K , Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
- (2016) K. Hudson et al. MOLECULAR CANCER THERAPEUTICS
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression
- (2016) Bernhard Englinger et al. Oncotarget
- Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors
- (2015) Vera A. Machado et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Thiazolidine-2,4-dione derivatives: Programmed chemical weapons for key protein targets of various pathological conditions
- (2015) Navriti Chadha et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers
- (2015) Bernard Barlaam et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
- (2015) C. Y. Cheah et al. BLOOD
- Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
- (2015) Carlotta Costa et al. CANCER CELL
- Lenvatinib: First Global Approval
- (2015) Lesley J. Scott DRUGS
- The discovery and development of sorafenib for the treatment of thyroid cancer
- (2015) Peter T White et al. Expert Opinion on Drug Discovery
- Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
- (2015) Ursula Matulonis et al. GYNECOLOGIC ONCOLOGY
- Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells
- (2015) James R. Henry et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors
- (2015) Rohit Arora et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecules in medicine mini-review: isoforms of PI3K in biology and disease
- (2015) Bart Vanhaesebroeck et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- RAF inhibitors that evade paradoxical MAPK pathway activation
- (2015) Chao Zhang et al. NATURE
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PI3 kinase in cancer
- (2015) Todd M. Bauer et al. PHARMACOLOGY & THERAPEUTICS
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
- (2015) Jorge Franco et al. Oncotarget
- Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
- (2014) D. A. J. van der Biessen et al. CLINICAL CANCER RESEARCH
- Idelalisib: First Global Approval
- (2014) Anthony Markham DRUGS
- Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602
- (2014) Anders Poulsen et al. Journal of Chemical Information and Modeling
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- (2014) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)
- (2014) Li Tan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- PharmDock: a pharmacophore-based docking program
- (2014) Bingjie Hu et al. Journal of Cheminformatics
- The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer
- (2013) Ulrich Lücking et al. ChemMedChem
- Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
- (2013) J. Tabernero et al. CLINICAL CANCER RESEARCH
- Polypharmacology in a Single Drug: Multitarget Drugs
- (2013) M. L. Bolognesi CURRENT MEDICINAL CHEMISTRY
- Trametinib: First Global Approval
- (2013) Cameron J. M. Wright et al. DRUGS
- Dabrafenib: First Global Approval
- (2013) Anita D. Ballantyne et al. DRUGS
- Synthesis and biological evaluation of guanidino analogues of roscovitine
- (2013) Iva Dolečková et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The discovery and development of vandetanib for the treatment of thyroid cancer
- (2013) Michael W Sim et al. Expert Opinion on Drug Discovery
- BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer
- (2013) Christian Rolfo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Therapeutic applications of PI3K inhibitors in cardiovascular diseases
- (2013) Alessandra Ghigo et al. Future Medicinal Chemistry
- Feasibility of Using Molecular Docking-Based Virtual Screening for Searching Dual Target Kinase Inhibitors
- (2013) Shunye Zhou et al. Journal of Chemical Information and Modeling
- QSAR Modeling: Where Have You Been? Where Are You Going To?
- (2013) Artem Cherkasov et al. JOURNAL OF MEDICINAL CHEMISTRY
- Emerging Topics in Structure-Based Virtual Screening
- (2013) Giulio Rastelli PHARMACEUTICAL RESEARCH
- Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
- (2013) Tara R. Rheault et al. ACS Medicinal Chemistry Letters
- Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics
- (2012) Do-Hee Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
- (2012) Vandana Lamba et al. CURRENT PHARMACEUTICAL DESIGN
- The Novel Therapeutic Effect of Phosphoinositide 3-Kinase- Inhibitor AS605240 in Autoimmune Diabetes
- (2012) J. Azzi et al. DIABETES
- Vandetanib
- (2012) James E. Frampton DRUGS
- Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors
- (2012) Joannah N'gompaza-Diarra et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases
- (2012) Marek Zatloukal et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Sorafenib in melanoma
- (2012) Joanna Mangana et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations
- (2012) Jiao Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Conformation-Specific Effects of Raf Kinase Inhibitors
- (2012) Xiaolun Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta
- (2012) Jeremy M. Murray et al. JOURNAL OF MEDICINAL CHEMISTRY
- SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo
- (2012) Y. Pan et al. MOLECULAR CANCER THERAPEUTICS
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Approaches to discover non-ATP site kinase inhibitors
- (2012) Lori Krim Gavrin et al. MedChemComm
- Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases
- (2011) Johanna Liebl et al. ANGIOGENESIS
- The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
- (2011) Arvin C. Dar et al. Annual Review of Biochemistry
- Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells
- (2011) Venkata Mahidhar Yenugonda et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors
- (2011) Stuart C. Wilson et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism
- (2011) Irene Sánchez-Hernández et al. CANCER LETTERS
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- Structural dissection of cyclin dependent kinases regulation and protein recognition properties
- (2011) Graziano Lolli CELL CYCLE
- Integrating structure-based and ligand-based approaches for computational drug design
- (2011) Gregory L Wilson et al. Future Medicinal Chemistry
- Kinase-Kernel Models: Accurate In silico Screening of 4 Million Compounds Across the Entire Human Kinome
- (2011) Eric Martin et al. Journal of Chemical Information and Modeling
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors
- (2011) Alexandra E. Gould et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity
- (2011) Radek Jorda et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
- (2011) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pyrazolopyridine Inhibitors of B-RafV600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors
- (2011) Steve Wenglowsky et al. ACS Medicinal Chemistry Letters
- The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796
- (2010) Justin Dietrich et al. BIOORGANIC & MEDICINAL CHEMISTRY
- A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors
- (2010) Abdel-Sattar S. Hamad Elgazwy et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941
- (2010) L. Salphati et al. DRUG METABOLISM AND DISPOSITION
- Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
- (2010) Christophe Le Tourneau et al. EUROPEAN JOURNAL OF CANCER
- Roscovitine-based CDK inhibitors acting as N-donor ligands in the platinum(II) oxalato complexes: Preparation, characterization and in vitro cytotoxicity
- (2010) Zdeněk Trávníček et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Targeting PI3K in neuroblastoma
- (2010) Volker Spitzenberg et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Quo Vadis, Virtual Screening? A Comprehensive Survey of Prospective Applications
- (2010) Peter Ripphausen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Targeted cancer therapies
- (2010) Saurabh Aggarwal NATURE REVIEWS DRUG DISCOVERY
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
- (2010) Kamil Paruch et al. ACS Medicinal Chemistry Letters
- Defining the conserved internal architecture of a protein kinase
- (2009) Alexandr P. Kornev et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Targeted Cancer Therapeutics
- (2009) William N. Hait CANCER RESEARCH
- Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma
- (2009) S. A. Aziz et al. CLINICAL CANCER RESEARCH
- Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer
- (2009) W.-S. Hsieh et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
- (2009) Kim-Son H. Nguyen et al. Clinical Lung Cancer
- Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
- (2009) Richard Morphy et al. CURRENT PHARMACEUTICAL DESIGN
- Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline
- (2009) Adrian L. Smith et al. JOURNAL OF MEDICINAL CHEMISTRY
- Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
- (2009) Fabio Zuccotto et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phosphatidylinositol-3-Kinase/Akt Signaling Pathway and Kidney Cancer, and the Therapeutic Potential of Phosphatidylinositol-3-Kinase/Akt Inhibitors
- (2009) Camillo Porta et al. JOURNAL OF UROLOGY
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Therapeutic Protein Kinase Inhibitors
- (2008) S. K. Grant CELLULAR AND MOLECULAR LIFE SCIENCES
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine
- (2008) K. Bettayeb et al. MOLECULAR CANCER THERAPEUTICS
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
- (2008) Beth Apsel et al. Nature Chemical Biology
- Network pharmacology: the next paradigm in drug discovery
- (2008) Andrew L Hopkins Nature Chemical Biology
- Drug discovery approaches targeting the PI3K/Akt pathway in cancer
- (2008) C Garcia-Echeverria et al. ONCOGENE
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started